The role of bevacizumab in the treatment of glioblastoma

Bevacizumab has been used in patients with GBM as a salvage therapy since its approval in the United States for recurrent GBM in 2009. In order to review the therapeutic effect of bevacizumab in the primary and recurrent clinical setting we have performed a systematic analysis of data from the publi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of neuro-oncology 2017-07, Vol.133 (3), p.455-467
Hauptverfasser:	Diaz, Roberto Jose, Ali, Sheikh, Qadir, Mehreen Gull, De La Fuente, Macarena I., Ivan, Michael E., Komotar, Ricardo J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Bevacizumab Bevacizumab - adverse effects Bevacizumab - therapeutic use Brain cancer Brain Neoplasms - drug therapy Cytotoxic agents Cytotoxicity Data processing Glioblastoma Glioblastoma - drug therapy Humans Immunotherapy Medicine Medicine & Public Health Monoclonal antibodies Neurology Oncology Quality of life Side effects Survival Targeted cancer therapy Topic Review Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!